Medikabazar goes for leadership boost

New Delhi: Medikabazar, India’s leading B2B online aggregator for medical supplies is in the cusp of massive growth. Hence, it has gone for leadership augmentation.

Medikabazaar recently announced the appointment of Dr. Akash Rajpal as Executive Vice-President, Marketing and Product Management. With more than 20 years of rich experience in public & private healthcare sectors, Dr Akash with a forte in healthcare operations & IT has executed various PPP, EHealth, Accreditation & operationally challenging initiatives.

An alumnus of Singularity University NASA AMES, Dr. Rajpal, a qualified medical graduate also holds post graduate credentials in administration, public health & finance. His achievements include receiving 1st NABH accreditation in Western region of India, IMC Ramkrishna Bajaj National Quality Award & Asia Pacific Quality Award.

Speaking about the new journey, Dr. Rajpal, said, “MedikaBazaar is an exciting opportunity where I’m fortunate to use my experience in technology, operations and clinical exposure to understand the supply chain & product need-gaps in the healthcare industry and help leverage my work experience to address them and be part of the company’s exponential growth”

Welcoming Dr. Rajpal, Mr. Vivek Tiwari, CEO, Medikabazaar, said, ““Dr Akash has been appointed as Executive Vice President Marketing & Product Management. Dr Akash has provided many valuable insights which have benefitted the organisation. I’m confident that Dr Akash’s rich diverse set of experience in IT, healthcare operations and business acumen as an entrepreneur himself, will help take the organization to greater heights”

Prior to this, his entrepreneurial initiative on innovative healthcare financing has got a case study published in Harvard Business Review and he has various papers on healthcare PPP to his credit. Besides, his past stints include working as COO at Jaslok Hospital & Research centre, Head HOSMAC Private LTD, & in various positions at Hiranandani hospital Powai & Navi Mumbai Municipal Corporation.

MedikaBazaar also recently appointed Mr Sanjeet Singh as EVP Operations & Revenue. Sanjeet comes with a rich experience of supply chain operations from telecom & healthcare industries, and prior to joining MedikaBazaar was heading central supply chain management & procurement at Fortis Healthcare.

Related Posts

A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

Healthy Heart is a Misnomer until underpinned by Regular Screening Bangaluru/ New Delhi: Of late, heart health has become kind of a veritable conundrum. We were never so unsure of…

Health Ministry Unveils Thalassemia Awareness Posters to Promote Early Screening

The aim is to encourage adolescents and antenatal women to undergo timely thalassemia screening New Delhi: The Ministry of Health and Family Welfare unveiled two awareness posters on thalassemia screening…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’